Pulse Biosciences develops medical devices based on nano-pulse stimulation (NPS), a non-thermal energy technology that uses ultra-short electrical pulses to affect cells. Its CellFX platform has been used in aesthetic dermatology for treating benign skin lesions such as sebaceous hyperplasia and seborrheic keratosis. The company focuses on expanding NPS applications across dermatology and other clinical settings where precise cellular effects with limited thermal damage are valuable.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -19.2 | — |
| Q3 2025 | 0.1 | — | -19.4 | — |
| Q4 2025 | 0.3 | — | -17.4 | — |
| Q1 2026 | 0.4 | — | -18.6 | — |
| Q2 2026 | 0.4 | — | -24.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Liberty Global Ltd. (LBTYK), Axcelis Technologies, Inc. (ACLS), GRAIL, Inc. (GRAL), National Energy Services Reunited Corp. (NESR), Firefly Aerospace Inc. (FLY), Atlanta Braves Holdings, Inc. (BATRA)